PRAX
Praxis Precision Medicines, Inc.
NASDAQ · USHealthcareBiotechnology
$304.43-3.17%
Price as of Jul 20, 2026
PRAX growth
Praxis Precision Medicines, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- -100.0%
- EBITDA
- -43.6%
- EBIT
- -53.4%
- EPS
- -24.9%
- Free cash flow
- -72.9%
- Operating cash flow
- -72.8%
Forward estimates
- Revenue
- —
- EBITDA
- +104.0%
- EPS
- -15.2%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- -66.1%
- EBIT
- -63.0%
- Net income
- -65.9%
- EPS
- -32.0%
- Free cash flow
- -89.1%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.